Latest Oncology News

NCCN Announces UC Davis Comprehensive Cancer Center as 31st Member Institution

April 16th 2021

Experts from Northern California-based cancer center to join panels responsible for evidence- based recommendations in NCCN Clinical Practice Guidelines and NCCN Guidelines for Patients, among other resources to improve outcomes for people with cancer.

Hutson Highlights Treatment Journey in Clear Cell RCC Case

April 16th 2021

Courtney Marabella

When considering which frontline option to administer to a patient with renal cell carcinoma, it is important to first understand which risk group they belong to.

TKIs, New Targets Serve as Active Areas of Exploration in Pancreatic and Extrapancreatic NETs

April 16th 2021

Hayley Virgil

Yoomi Lee, MD, discusses the safety profile of surufatinib and highlighted future directions for patients with pancreatic and extrapancreatic neuroendocrine tumors.

Accelerating Advances in NSCLC Underscore the Importance of Accessibility

April 16th 2021

Caroline Seymour

Jacob Sands, MD, discussed current approaches to the treatment of patients with early-stage and locally advanced non–small cell lung cancer.

Unique Landscape of Actionable Pathogenic Variants Unfolds in Breast and Ovarian Cancers in the Caribbean

April 16th 2021

Hayley Virgil

Sophia George, PhD, and Judith E. Hurley, MD, discuss the importance of the genetic association study, challenges faced with launching such an effort, the key findings from the research, and the clinical implications of the data in the Caribbean as well as the United States

Latest Oncology Videos

All Oncology News

FDA Approves Nivolumab Plus Chemo for Frontline Gastric Cancer

April 16th 2021

Kristi Rosa

The FDA has approved nivolumab to be combined with select types of chemotherapy for the frontline treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.

Tazemetostat Displays Promising Preclinical Activity in BTK-Resistant MCL Cell Lines

April 16th 2021

Caroline Seymour

Tazemetostat as a single agent or in combination with zanubrutinib demonstrated antitumor activity in mantle cell lymphoma cell lines with intrinsic resistance to BTK inhibitors, suggesting that the agent could be a promising therapeutic option for patients with primary relapsed/refractory disease.

NK Cell–Targeting Strategies Come Into Their Own

April 16th 2021

Jane de Lartigue, PhD

Although anticancer therapies that leverage T cells have commanded the most attention in the immuno-oncology era of the past decade, strategies based on natural killer cells have recently emerged as attractive approaches.

Making the Choice: Osseus Reattachment of the Greater Trochanter Vs Soft Tissue–Only Abductor Repair in Bone Cancers

April 16th 2021

Gina Mauro

Reattaching the greater trochanter to the proximal femur endoprosthesis did not show an improvement in Trendelburg gait or reliance on an assistive ambulatory device vs a soft tissue–only abductor repair in patients with bone cancers.

Addition of SDX-7320 to Palbociclib Inhibits Tumor Growth in Breast Cancer Xenografts

April 15th 2021

Hayley Virgil

The addition of SDX-7320, a novel inhibitor of methionine aminopeptidase 2, to palbociclib was found to inhibit MCF-7 tumor growth and reduce the expression of proteins associated with resistance to palbociclib.

Research Reflections: Sonpavde on Urothelial Cancer Updates From the 2021 GU Cancers Symposium

April 15th 2021

OncLive Staff

Dr. Sonpavde discusses key data presented during the 2021 Genitourinary Cancers Symposium in urothelial carcinoma and anticipated research directions with immunotherapy, chemotherapy, and antibody-drug conjugates.

Pal Previews Potential Avenues to Produce More Second-Line Options and Beyond in RCC

April 15th 2021

Hayley Virgil

Sumanta K. Pal, MD, details ongoing research efforts dedicated to providing additional therapeutic options for patients with renal cell carcinoma in the second-line setting and beyond.

31-Gene Expression Profile Test Improves Risk Assessment in Cutaneous Melanoma

April 15th 2021

Courtney Marabella

Combining the 31-gene expression profile test with current American Joint Committee on Cancer staging guidelines may improve risk assessment in patients with cutaneous melanoma, as well as determine which patients could be candidates for more intense follow-up.

CAR T-Cell Therapy Enters the Arena in Multiple Myeloma With Ongoing Research Ahead

April 15th 2021

Jessica Hergert

Saad Z. Usmani, MD, FACP, discusses the rapidly changing cellular therapy paradigm in relapsed/refractory multiple myeloma.

Chronic irAEs After Adjuvant Anti–PD-1 Therapy More Common Than Previously Recognized in High-Risk Resected Melanoma

April 15th 2021

Courtney Marabella

Chronic immune-related adverse effects arising from adjuvant anti–PD-1 therapy in patients with high-risk melanoma are more common than previously recognized, and often persisted with longer follow-up.

Chemoimmunotherapy Prolongs Time to Disease Recurrence, But Work Remains to Deliver Durable Benefit in ES-SCLC

April 15th 2021

Caroline Seymour

The combination of atezolizumab, carboplatin, and etoposide, as well as durvalumab, etoposide, and platinum chemotherapy, each have shown survival improvements vs chemotherapy alone as frontline therapy in patients with extensive-stage small cell lung cancer.

Overall Survival After Surgery for Spinal Metastases Has Improved Over the Past Two Decades

April 15th 2021

Ori Barzilai, MD

Postoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.

Novel Agents Move the Needle Forward in Metastatic Pancreatic Cancer

April 15th 2021

Courtney Marabella

Raymond Wadlow, MD, discusses the emergence of combination chemotherapy regimens in metastatic pancreatic cancer and the promise of emerging strategies that are under exploration.

Frontline Nivolumab/Cabozantinib Approved in Europe for Advanced RCC

April 14th 2021

Kristi Rosa

The European Commission has approved the combination of nivolumab and cabozantinib as a frontline treatment in patients with advanced renal cell carcinoma.

Triplet Combos Targeting ER, CDK4/6, and PIK3CA Inhibit Tumor Growth in ER+ Breast Cancer

April 14th 2021

Courtney Marabella

A triplet combination regimen that targets PIK3CA mutations, ER, and CDK4/6 can reduce and inhibit tumor growth in preclinical models of estrogen receptor–positive breast cancer that is resistant to fulvestrant plus a CDK4/6 inhibitor or PI3K inhibitor.

See All News

x